Blincyto® (blinatumomab) – Expanded dosing and new warnings
September 1, 2016 – Amgen announced the FDA approval of Blincyto (blinatumomab) to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Top